tetano
Editor, Senior Moderator
iScience
. 2023 Sep 19;26(10):107959.
doi: 10.1016/j.isci.2023.107959. eCollection 2023 Oct 20. Third COVID-19 vaccine dose boosts antibody function in Rwandans with high HIV viral load
Cynthia L Swan[SUP] 1 [/SUP], Valentine Dushimiyimana[SUP] 2 [/SUP], Pacifique Ndishimye[SUP] 3 4 [/SUP], Rachelle Buchanan[SUP] 1 [/SUP], Anthony Yourkowski[SUP] 1 5 [/SUP], Sage Semafara[SUP] 6 [/SUP], Sabin Nsanzimana[SUP] 7 [/SUP], Magen E Francis[SUP] 1 5 [/SUP], Brittany Thivierge[SUP] 1 [/SUP], Jocelyne Lew[SUP] 1 [/SUP], Antonio Facciuolo[SUP] 1 8 [/SUP], Volker Gerdts[SUP] 1 8 [/SUP], Darryl Falzarano[SUP] 1 8 [/SUP], Calvin Sjaarda[SUP] 9 10 [/SUP], David J Kelvin[SUP] 3 [/SUP], Leopold Bitunguhari[SUP] 11 [/SUP], Alyson A Kelvin[SUP] 1 5 [/SUP]
Affiliations
SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) causing COVID-19 (coronavirus disease 2019) poses a greater health risk to immunocompromized individuals including people living with HIV (PLWH). However, most studies on PLWH have been conducted in higher-income countries. We investigated the post-vaccination antibody responses of PLWH in Rwanda by collecting peripheral blood from participants after receiving a second or third COVID-19 vaccine. Virus-binding antibodies as well as antibody neutralization ability against all major SARS-CoV-2 variants of concern were analyzed. We found that people with high HIV viral loads and two COVID-19 vaccine doses had lower levels of binding antibodies that were less virus neutralizing and less cross-reactive compared to control groups. A third vaccination increased neutralizing antibody titers. Our data suggest that people with high HIV viral loads require a third dose of vaccine to neutralize SARS-CoV-2 virus and new variants as they emerge.
Keywords: Public health; Virology.
. 2023 Sep 19;26(10):107959.
doi: 10.1016/j.isci.2023.107959. eCollection 2023 Oct 20. Third COVID-19 vaccine dose boosts antibody function in Rwandans with high HIV viral load
Cynthia L Swan[SUP] 1 [/SUP], Valentine Dushimiyimana[SUP] 2 [/SUP], Pacifique Ndishimye[SUP] 3 4 [/SUP], Rachelle Buchanan[SUP] 1 [/SUP], Anthony Yourkowski[SUP] 1 5 [/SUP], Sage Semafara[SUP] 6 [/SUP], Sabin Nsanzimana[SUP] 7 [/SUP], Magen E Francis[SUP] 1 5 [/SUP], Brittany Thivierge[SUP] 1 [/SUP], Jocelyne Lew[SUP] 1 [/SUP], Antonio Facciuolo[SUP] 1 8 [/SUP], Volker Gerdts[SUP] 1 8 [/SUP], Darryl Falzarano[SUP] 1 8 [/SUP], Calvin Sjaarda[SUP] 9 10 [/SUP], David J Kelvin[SUP] 3 [/SUP], Leopold Bitunguhari[SUP] 11 [/SUP], Alyson A Kelvin[SUP] 1 5 [/SUP]
Affiliations
- PMID: 37810226
- PMCID: PMC10558770
- DOI: 10.1016/j.isci.2023.107959
SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) causing COVID-19 (coronavirus disease 2019) poses a greater health risk to immunocompromized individuals including people living with HIV (PLWH). However, most studies on PLWH have been conducted in higher-income countries. We investigated the post-vaccination antibody responses of PLWH in Rwanda by collecting peripheral blood from participants after receiving a second or third COVID-19 vaccine. Virus-binding antibodies as well as antibody neutralization ability against all major SARS-CoV-2 variants of concern were analyzed. We found that people with high HIV viral loads and two COVID-19 vaccine doses had lower levels of binding antibodies that were less virus neutralizing and less cross-reactive compared to control groups. A third vaccination increased neutralizing antibody titers. Our data suggest that people with high HIV viral loads require a third dose of vaccine to neutralize SARS-CoV-2 virus and new variants as they emerge.
Keywords: Public health; Virology.